Innovent Biologics IncOTCIVBIY and Eli Lilly And CoLLY 0.55% have announced new and updated data from the ORIENT-11 Phase 3 study of sintilimab as first-line treatment of nonsquamous non-small cell lung cancer (NSCLC).
The trial assessed sintilimab in combination with pemetrexed and platinum chemotherapy.
